Supernus Pharmaceuticals, Inc. (SUPN)
26.16
-0.58
(-2.17%)
USD |
NASDAQ |
Nov 06, 16:00
26.19
+0.03
(+0.11%)
After-Hours: 20:00
Supernus Pharmaceuticals Free Cash Flow : 86.96M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 86.96M |
| June 30, 2026 | 18.79M |
| March 31, 2026 | 82.24M |
| December 31, 2025 | 45.99M |
| September 30, 2025 | 70.75M |
| June 30, 2025 | 185.86M |
| March 31, 2025 | 163.34M |
| December 31, 2024 | 171.23M |
| September 30, 2024 | 172.03M |
| June 30, 2024 | 154.43M |
| March 31, 2024 | 99.84M |
| December 31, 2023 | 110.53M |
| September 30, 2023 | 93.11M |
| June 30, 2023 | 71.08M |
| March 31, 2023 | 161.81M |
| December 31, 2022 | 116.41M |
| September 30, 2022 | 137.56M |
| June 30, 2022 | 119.72M |
| March 31, 2022 | 94.29M |
| December 31, 2021 | 125.08M |
| September 30, 2021 | 107.98M |
| June 30, 2021 | 117.45M |
| March 31, 2021 | 162.57M |
| December 31, 2020 | 134.71M |
| September 30, 2020 | 144.85M |
| Date | Value |
|---|---|
| June 30, 2020 | 176.73M |
| March 31, 2020 | 114.00M |
| December 31, 2019 | 140.39M |
| September 30, 2019 | 131.25M |
| June 30, 2019 | 156.04M |
| March 31, 2019 | 133.57M |
| December 31, 2018 | 127.33M |
| September 30, 2018 | 129.26M |
| June 30, 2018 | 104.96M |
| March 31, 2018 | 118.34M |
| December 31, 2017 | 101.46M |
| September 30, 2017 | 84.94M |
| June 30, 2017 | 66.57M |
| March 31, 2017 | 59.90M |
| December 31, 2016 | 46.39M |
| September 30, 2016 | 43.41M |
| June 30, 2016 | 22.44M |
| March 31, 2016 | 19.80M |
| December 31, 2015 | 21.51M |
| September 30, 2015 | 11.97M |
| June 30, 2015 | 39.22M |
| March 31, 2015 | 20.91M |
| December 31, 2014 | 2.635M |
| September 30, 2014 | -12.94M |
| June 30, 2014 | -54.44M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| ANI Pharmaceuticals, Inc. | 167.52M |
| Prestige Consumer Healthcare, Inc. | 235.36M |
| Structure Therapeutics, Inc. | -225.05M |
| Corcept Therapeutics, Inc. | 194.62M |
| Veru, Inc. | -26.04M |